Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Currently submitted to: JMIR Formative Research

Date Submitted: Oct 21, 2026

Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.

Early HTA of a home-based uroflowmetry using experimental simulation with urologists in Thailand

  • Apiwat Piriyapol; 
  • Chavalit Honglertsakul; 
  • Phornphob Naiyanetr; 
  • Yot Teerawattananon; 
  • Yi Wang; 
  • Teerawat Wiwatpanit

ABSTRACT

Background:

Early health technology assessment (HTA) can guide the development of medical devices before clinical effectiveness data are available. Home-based uroflowmetry may overcome the limitations of single office-based measurements in men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH), but its clinical and economic value in Thailand is unknown.

Objective:

This study aimed to assess the potential clinical and economic value of a home-based uroflowmetry device for LUTS/BPH in Thailand and to define a target product profile (TPP) to guide its further development.

Methods:

A mixed methods early HTA was used, comprising (1) a targeted landscape review of diagnostic practice and reimbursement, (2) an experimental simulation in which 10 urologists were randomly assigned to office-based uroflowmetry only (control=5) or a choice of office-based or home-based uroflowmetry (intervention, n=5) and managed 3 deidentified patient cases over 2 simulated visits, and (3) early economic modelling over a 3-month horizon from the Thai health system perspective. Diagnostic accuracy was estimated from urologists’ confidence scores. A deterministic sensitivity analysis varied the cost multiplier for misdiagnosis (M) from 1.0 to 2.0

Results:

The landscape review identified gaps in diagnostic accessibility and variable reimbursement mechanisms. In the simulation, 3 of 5 intervention-group urologists used the home-based device, all in the most diagnostically complex case (Case 3). In that case, mean diagnostic confidence in the intervention group rose from 78% to 96% between visits, compared with 62% to 58% in the control group; treatment decisions were unchanged. Investigation costs were 2,378 Thai baht (THB) higher and treatment costs 301 THB lower than in the control group, a net increase of 2,077 THB per case. At the base-case cost multiplier, the device remained more costly; when misdiagnosis doubled downstream costs, it reached cost equivalence at 89.7% accuracy and was cost-saving at the observed accuracy (−471 THB per case). The target product profile (TPP) specifies a minimum diagnostic accuracy of 80% and an optimal accuracy of 90%, alongside cost, usability, and workflow requirements.

Conclusions:

Home-based uroflowmetry may complement office-based testing in diagnostically complex LUTS/BPH by increasing diagnostic confidence, but its economic value depends on diagnostic accuracy and the cost of misdiagnosis. The TPP provides benchmarks for further device development and clinical validation. Clinical Trial: Non


 Citation

Please cite as:

Piriyapol A, Honglertsakul C, Naiyanetr P, Teerawattananon Y, Wang Y, Wiwatpanit T

Early HTA of a home-based uroflowmetry using experimental simulation with urologists in Thailand

JMIR Preprints. 21/10/2026:114906

DOI: 10.2196/preprints.114906

URL: https://preprints.jmir.org/preprint/114906

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.